Self-sampling Blood Collection and Storage Devices Market By Product Type (Collection Kits, Lancets, DBS Cards, Microsampling Devices, Accessories); By Sample Type (Whole Blood, Plasma/Serum, Dried Blood Spots); By Application (Diagnostic Testing, Genomics, Biomarker Discovery, Clinical Trials); By End User (Clinical Laboratories, Home-Based Users, CROs, Biobanks); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Self-Sampling Blood Collection And Storage Devices Market will witness a robust CAGR of 10.9% , valued at USD 1.12 billion in 2024 , and projected to reach approximately USD 2.1 billion by 2030 , according to Strategic Market Research.

 

This market sits at the intersection of two growing healthcare trends: decentralization and personalization. Self-sampling blood devices—designed for non-clinical settings—allow users to draw, store, and sometimes process their own blood samples with minimal supervision. These solutions are no longer niche or experimental. In many diagnostic pathways, they’re becoming an integral part of early screening, longitudinal health tracking, and even decentralized clinical trials.

 

The strategic relevance of this market in 2024–2030 is rooted in a few converging factors. First, the push toward home-based diagnostics has gained irreversible momentum. Global healthcare systems—pressured by cost, access, and capacity—are increasingly favoring tools that shift testing outside the clinic. Self-collection kits fit that narrative perfectly. Second, digital health platforms are beginning to treat blood biomarkers as a standard input—on par with heart rate or sleep cycles—feeding into AI-driven health engines. For that to work, easy and repeatable sample collection is critical.

 

From a public health lens, these tools support wider surveillance and participation. Whether it’s for population-wide genomic studies or chronic disease management in underserved areas, the ability to ship a reliable self-collected sample unlocks access at scale. The devices also support patient autonomy—allowing users to participate in their health monitoring without geographic or scheduling constraints.

 

Key stakeholders here include OEMs building collection kits and microsampling technologies, diagnostic companies integrating self-sampling into their test workflows, contract research organizations (CROs) using these devices for remote trial protocols, and biobanks optimizing collection efficiency. Governments are taking interest too, especially where self-sampling aids in infectious disease tracking, genetic screening, or rural health outreach.

 

Unlike traditional phlebotomy-dependent models, this space is redefining what’s possible in fluid-based diagnostics. The rise of dried blood spot (DBS) cards, volumetric absorptive microsampling (VAMS), and capillary-based microfluidics is pushing the limits of sample size, stability, and usability. Some devices now enable multiplexed biomarker detection from a fingertip-sized sample, usable days after collection.

 

To be honest, self-sampling blood collection isn’t just a convenience story —it’s a system-level unlock. It breaks barriers in research, diagnostics, and monitoring all at once. And over the next few years, it’s set to evolve from “nice-to-have” to “standard offering” across multiple verticals.

 

Market Segmentation And Forecast Scope

The self-sampling blood collection and storage devices market cuts across multiple product and service layers—each driven by slightly different user needs, scientific requirements, and logistical constraints. Below is a strategic breakdown of the core segmentation framework that defines this evolving market.

By Product Type

The market includes various devices designed to simplify and stabilize sample collection in non-clinical settings. These range from fingerstick-based collection kits and lancets to more advanced platforms like volumetric microsampling devices and vacuum-sealed DBS (dried blood spot) cards.

Among these, dried blood collection kits currently account for a notable share due to their ease of use, long-term sample stability, and minimal biohazard risks during transport. However, newer devices incorporating microfluidics and integrated storage capsules are growing fast, especially those that eliminate the need for cold-chain logistics.

 

By Sample Type

Most devices in the market are configured for whole blood, plasma/serum, or dried blood spots. DBS-based self-collection is especially popular in genetic testing, newborn screening, and chronic disease biomarker analysis. Whole blood devices, while less stable without refrigeration, are gaining ground due to their compatibility with rapid testing platforms and multi-omics workflows.

A growing subset of players is focusing on plasma separation at point-of-care, using integrated filtration membranes to simplify downstream analysis. This might soon expand sample type flexibility without burdening users with lab-like processes.

 

By Application

Applications range from diagnostic testing and genomics to biomarker discovery, epidemiological surveillance, and decentralized clinical trials. Diagnostic testing dominates today’s landscape, but the genomics segment is expanding rapidly— fueled by direct-to-consumer companies and population health initiatives.

Emerging use cases also include longitudinal monitoring in oncology, pharmacokinetic profiling in remote trials, and even mental health research, where cytokine or hormone levels are monitored over time.

In 2024, diagnostic testing comprises the largest application segment, but genomics and decentralized research are expected to outpace it in growth rate through 2030.

 

By End User

This market serves a mix of institutional and individual users. Key segments include clinical laboratories, home-based consumers, CROs, and biobanking networks. Each has a different reason to adopt self-sampling.

For labs and CROs, the benefit lies in scale—being able to receive hundreds of stable, labeled samples from patients without scheduling logistics or collection site overhead. For end consumers, the appeal is privacy, autonomy, and convenience—especially in chronic disease testing or wellness optimization.

Biobanks, too, are ramping up remote collection, particularly when enrolling participants across rural or underserved regions where in-person phlebotomy isn’t feasible.

 

By Region

Geographically, adoption is strongest in North America and Europe, where regulatory frameworks, digital health ecosystems, and patient familiarity with remote testing already exist. That said, the Asia Pacific region is expected to grow the fastest through 2030, driven by expanding genomics initiatives in China and India, government-led diagnostics rollouts, and emerging medtech ecosystems.

Regions like Latin America, the Middle East, and Africa are still early in adoption, but rising interest in infectious disease tracking and decentralized trials is opening the door to low-cost, ambient-stable self-sampling tools.

 

Market Trends And Innovation Landscape

Self-sampling blood collection isn’t just a shipping-and-handling upgrade—it’s quickly becoming one of the most actively innovated categories in diagnostics and clinical research. Device makers, biotech firms, and digital health startups are converging on this space with ideas that stretch far beyond basic fingerstick kits.

Microfluidics and Volumetric Control Are Becoming the Standard

Early self-sampling kits often relied on rudimentary droplet collection—messy, imprecise, and difficult to standardize. Today, next-gen devices integrate microfluidic channels and volumetric absorptive microsampling (VAMS) technologies that enable precise collection of 10–30 microliters per sample. These tools ensure quantitative accuracy even when users are untrained.

Some of the more advanced platforms now use hydrophilic coatings and vacuum-based draw mechanisms to automate the process entirely—making the experience safer, faster, and more consistent across demographics.

One product lead at a European diagnostics firm recently noted that their self-collection kit now delivers error margins below 5%, rivaling in-clinic phlebotomy.

 

Stabilization Technologies Are Extending Shelf Life and Reach

Stabilizing whole blood or plasma without refrigeration used to be a major bottleneck. Now, filter-based stabilization matrices, desiccant technologies, and chemically pre-treated collection cards allow samples to remain viable for days or even weeks at room temperature.

This innovation isn’t just about convenience—it’s a game-changer for population-scale studies, humanitarian health programs, and decentralized trials in low-resource settings. The ability to maintain RNA, DNA, or protein integrity outside of cold chain opens up entirely new geographies and use cases.

 

Integration With Digital Health Platforms Is Accelerating

Self-sampling is now often embedded in broader care platforms. Diagnostic players are offering app-connected kits where users get instructions, tracking, and test results in one interface. Some even include video capture during collection to ensure procedural compliance for regulatory-grade samples.

Data from these kits is increasingly being piped into EHRs, wellness dashboards, and AI-driven health models. That creates a two-way loop where sample quality improves through feedback—and results are more actionable thanks to contextual layering.

This digital integration also makes self-sampling more usable in longitudinal monitoring —for example, chronic inflammation tracking in autoimmune disorders or hormone cycling in fertility planning.

 

Decentralized Trials Are Driving Institutional Adoption

Contract research organizations and pharma sponsors are adopting self-sampling kits to reduce site visits in clinical trials. This shift is especially strong in oncology, neurology, and rare disease studies, where patients are geographically scattered or immunocompromised.

The demand here is for high-integrity kits that offer time-stamped logging, tamper-evident packaging, and integration with lab LIMS (Laboratory Information Management Systems). Several device makers are now positioning their kits specifically for GCP-compliant remote trial workflows.

In one example, a decentralized oncology study in the U.S. used self-sampling kits for PK/PD tracking and cut trial site overhead by nearly 35%.

 

Sustainability and Minimal Waste Design Are Emerging Differentiators

As adoption scales, waste management is starting to surface as a concern. Some device manufacturers are now exploring biodegradable components , low-plastic packaging , and single-use cartridge systems that minimize both biohazard and environmental impact. This is becoming particularly important in public health programs and regulated procurement bids.

To be honest, this market’s innovation wave is just getting started. We’re moving from “can we collect blood remotely?” to “how can we make it frictionless, integrated, and intelligent?”

 

Competitive Intelligence And Benchmarking

While the self-sampling blood collection and storage devices market may still be emerging, the competitive dynamics are evolving fast. What began as a niche field dominated by startups is now attracting larger diagnostics and medical device firms, many of whom see this as a strategic extension of decentralized healthcare and personalized diagnostics.

Tasso

Tasso is one of the most recognized players in this space. Known for its push-button blood collection devices, the company has built a reputation around painless sampling and high user compliance. Tasso’s devices are already being used in decentralized clinical trials and remote wellness programs across the U.S.

The company’s edge lies in combining patented capillary blood collection with logistics support and lab partnerships. Their FDA clearance for at-home use places them in a strong regulatory position—something most newer entrants lack.

 

Neoteryx (A Mitra Company)

Neoteryx specializes in volumetric absorptive microsampling (VAMS), offering solutions used in both clinical and research environments. Their Mitra devices are widely adopted for dried blood spot collection in pharmacokinetic studies, epidemiology, and remote diagnostics.

They’ve built strong credibility among CROs and academic institutions for their validated performance and compatibility with mass spectrometry workflows. Integration with lab systems and sample tracking tools gives them an edge in enterprise use.

 

Seventh Sense Biosystems

This company introduced one of the earliest user-friendly devices designed to collect blood painlessly from the upper arm via microneedles. Their platform targets wellness and routine diagnostics segments, and though not as widely deployed as Tasso, its design-first approach has influenced many newer kits.

Their strategy focuses on human- centered design—making self-sampling acceptable to needle-averse users, which is a real barrier in many segments.

 

Spot On Sciences

Spot On Sciences, acquired by a diagnostics company, offers the HemaSpot platform for remote blood collection. Their technology focuses on self-drying and ambient-stable sampling, ideal for research settings and global health programs. The platform is often used where lab infrastructure is weak but surveillance needs are high.

The company’s positioning is less about consumer convenience and more about rugged performance in field conditions—a niche but growing need.

 

YourBio Health

Previously branded as Seventh Sense, YourBio Health rebranded and now positions itself for high-compliance clinical settings. They are also investing in partnerships with diagnostic labs and digital health platforms to enable seamless logistics from collection to results.

 

Other Notable Mentions

Large diagnostics players like Labcorp and Quest Diagnostics are beginning to test partnerships or develop proprietary kits. While not hardware-first companies, their entry could shift the market dynamics quickly due to their distribution power and brand trust.

Some biotech firms are also building verticalized kits for specific disease areas—like oncology, fertility, or cardiometabolic risk—bundling biomarkers with at-home collection as a single product.

Across the board, the differentiators are becoming clear: painless or user-friendly collection, ambient-stable storage, regulatory approval, and seamless lab or platform integration. Price matters, especially in public procurement, but reliability and compliance dominate decision-making in clinical and research segments.

To be honest, this isn’t a winner-takes-all market. It’s a space where specific use cases reward specific design choices—and the winners will be those who deeply understand their user, whether that’s a rural patient, a CRO trial manager, or a wellness app building engagement through biometrics.

 

Regional Landscape And Adoption Outlook

Adoption of self-sampling blood collection and storage devices looks different depending on geography. Some regions are leaning into it as a cornerstone of remote care and research; others are still sorting through infrastructure, regulation, and patient awareness. Below is a closer look at how regional dynamics are shaping this market’s trajectory.

North America

North America leads the market in both innovation and adoption. The U.S. in particular has seen strong uptake, driven by a mature diagnostics ecosystem, growing investment in decentralized clinical trials, and a highly active direct-to-consumer health tech space.

Regulatory clarity from the FDA around at-home blood collection has encouraged rapid scaling among startups and established labs alike. Companies like Tasso and YourBio Health have launched FDA-cleared devices, while Labcorp and Quest Diagnostics are piloting home-based collection programs.

What’s also notable is the reimbursement environment. Private payers are beginning to recognize self-collected samples as valid in select testing protocols, especially in chronic care management. This paves the way for broader integration into primary care and virtual health models.

Canada mirrors much of the U.S. ecosystem, though with tighter national health protocols and a more measured pace of rollout. That said, Canadian research institutions are actively deploying self-sampling in genomics and rare disease studies.

 

Europe

Europe remains a strong second in terms of infrastructure and innovation, though adoption varies by country. The UK, Germany, and the Nordics are leading due to their well-established biobanking frameworks, public health research agendas, and openness to decentralized trials.

The European Medicines Agency and country-level regulatory bodies have supported the use of self-collected samples in post-marketing surveillance and real-world evidence programs. Meanwhile, the EU’s push for broader health data standardization is opening the door for integration between digital health records and at-home diagnostics.

France and Southern Europe are still in earlier stages of adoption, with more fragmented regulations and limited consumer-facing diagnostics companies. However, several governments are now funding pilot programs in rural diagnostics and population health screening using self-sampling tools.

 

Asia Pacific

Asia Pacific is the fastest-growing region by CAGR. China and India are experiencing sharp demand due to large-scale population genomics initiatives, rapid growth in health-tech startups , and government interest in low-cost diagnostic accessibility.

In India, self-sampling is being explored as a solution for screening in tier 2 and tier 3 cities where phlebotomy resources are scarce. In China, digital health platforms are embedding these devices into wellness and fertility testing subscriptions targeted at the urban middle class.

Japan and South Korea, while smaller in population, are setting standards in microdevice innovation. Several Japanese firms are piloting integration between self-sampling and remote patient monitoring platforms—especially in elderly care.

Still, regulatory approval paths in this region are more complex and less harmonized, slowing broader commercial rollouts.

 

Latin America, Middle East, and Africa (LAMEA)

LAMEA represents both the biggest challenge and the biggest untapped potential. Infrastructure gaps, regulatory ambiguity, and affordability remain key barriers. But things are changing.

In Brazil, the government and private insurers are piloting remote diagnostics for rural populations, with dried blood spot kits playing a central role. Mexico is seeing some adoption among wellness providers and mobile clinics.

In the Middle East, countries like the UAE and Saudi Arabia are investing in smart health initiatives that include remote sampling for chronic disease management. These are usually bundled with teleconsultation services.

In Sub-Saharan Africa, self-sampling is starting to gain traction in HIV and hepatitis surveillance programs run by NGOs and global health donors. The value proposition here is clear—minimal equipment, long sample stability, and no cold chain requirements.

Overall, regional adoption depends heavily on how well self-sampling devices can integrate into existing healthcare models—whether that’s consumer-first, research-led, or public health-driven. Infrastructure helps, but what really matters is trust. If users believe the sample they collect will be accurate, respected, and useful—they’ll keep using it.

 

End-User Dynamics And Use Case

The self-sampling blood collection and storage devices market serves a unique mix of end users, each with distinct motivations, constraints, and operational realities. Unlike traditional diagnostics, this market requires manufacturers to design around users who aren’t trained medical professionals—whether they’re patients at home, study participants, or researchers in remote locations.

Clinical Laboratories

For diagnostic labs, self-sampling solves logistical headaches. Instead of coordinating in-person phlebotomy appointments, labs can distribute kits directly to patients, receive labeled , barcoded samples by mail, and process them at scale. This model is especially effective in chronic disease management, HIV monitoring, and pharmacogenomic testing, where patients need to be tested regularly without coming into a clinic.

Larger labs are also adopting these tools to support partnerships with D2C health platforms and digital wellness providers. The real value isn’t just operational—it’s access. Self-sampling opens up entire demographics that may never walk into a diagnostic center but will mail a kit from home.

 

Contract Research Organizations (CROs)

CROs are emerging as one of the most aggressive adopters of self-sampling. In decentralized clinical trials, where patient recruitment and retention hinge on convenience, being able to collect biomarker data without a site visit is critical.

These organizations use self-sampling kits for longitudinal blood draws, PK/PD studies, and biomarker validation in rare disease trials. They prioritize devices that are pre-validated for sample stability, tamper-proofing, and lab compatibility.

One CRO executive mentioned that switching to self-collected kits reduced missed appointments by over 60% in a year-long immunology trial conducted across five countries.

 

Biobanks and Research Institutions

Biobanks increasingly rely on self-sampling to scale participant enrollment , especially in rural, low-access, or high-volume populations. Whether collecting samples for genomic diversity studies or longitudinal epidemiology, these institutions value ambient-stable devices that can be shipped in bulk, used independently, and stored with minimal infrastructure.

Some public health programs are distributing DBS kits nationwide to enable early-life genetic screening or infectious disease tracking—without overloading local clinics.

 

Home-Based Consumers

At-home users form a fast-growing segment. Many are engaging through wellness apps, fertility trackers, or digital health startups offering tests for hormones, inflammation markers, or metabolic health. Others are managing chronic conditions like diabetes, thyroid disorders, or cardiovascular risk with periodic self-testing.

This group prioritizes ease of use, minimal discomfort, and fast turnaround for results. Their loyalty depends on trust—how accurate the test feels, how private the process is, and how quickly insights arrive.

Devices designed for this audience are competing not only on clinical metrics but also on packaging, instruction clarity, and digital experience.

 

Hospitals and Clinics

Traditional providers are less prominent but not absent. Some are starting to use self-sampling devices for pre-operative testing, post-discharge monitoring, or outreach to patients who skip follow-ups. However, most still rely on in-clinic phlebotomy and have yet to integrate self-sampling into standard protocols.

Over time, hybrid models may emerge—where patients are given kits to collect follow-up samples at home rather than return to the clinic.

 

Use Case Highlight

A population genomics initiative in the UK needed to collect blood samples from over 100,000 participants across urban and rural settings—without expanding physical infrastructure or staffing. The team deployed a self-sampling strategy using ambient-stable DBS kits mailed directly to participants’ homes.

Participants followed video-guided instructions, returned samples via prepaid envelopes, and completed optional surveys through a connected app. Over 85% of the kits were returned within 10 days, and sample integrity exceeded lab thresholds for DNA yield and quality.

This allowed researchers to collect robust biomarker data at national scale—at a fraction of the cost of traditional in-clinic sampling.

Ultimately, this market isn't just about the device. It's about meeting people where they are—whether that’s a lab tech juggling throughput, a trial participant in a remote village, or a working parent squeezing in a hormone test between meetings.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Tasso received FDA Class II clearance in 2023 for its at-home blood collection device, expanding its use in decentralized clinical trials and remote diagnostics workflows.

• Neoteryx announced a partnership in 2024 with a leading global CRO to integrate Mitra® devices into long-term pharmacokinetic studies in oncology.

• YourBio Health launched a painless microsampling platform for use in personalized health tracking, supported by integrations with mobile diagnostics apps.

• A European research consortium piloted biodegradable self-sampling kits for use in climate-conscious public health programs, showing strong viability across rural regions.

• A major diagnostic lab in India began deploying DBS-based self-sampling kits for national metabolic screening programs, particularly in underserved districts.

 

Opportunities

• Decentralized Clinical Trials: Sponsors and CROs are actively adopting self-sampling to reduce site visit frequency and expand geographic recruitment.

• Population Genomics & Screening: National health initiatives in Asia and Europe are leveraging self-sampling kits to collect biospecimens at scale, especially for DNA and metabolomic profiling.

• D2C Health Integrations: Digital wellness and chronic disease management platforms are embedding self-collection kits to create closed-loop diagnostics without clinic touchpoints.

 

Restraints

• Regulatory Variation: Approval and usage guidelines vary widely between countries, delaying global rollout and complicating partnerships with labs and payers.

• User Compliance & Training: Inconsistent sample quality from untrained users remains a challenge, especially in first-time use or elderly populations without support.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.12 Billion
Revenue Forecast in 2030	USD 2.1 Billion
Overall Growth Rate	CAGR of 10.9% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Sample Type, By Application, By End User, By Geography
By Product Type	Collection Kits, Lancets, DBS Cards, Microsampling Devices, Accessories
By Sample Type	Whole Blood, Plasma/Serum, Dried Blood Spots
By Application	Diagnostic Testing, Genomics, Biomarker Discovery, Clinical Trials
By End User	Clinical Laboratories, Home-Based Users, CROs, Biobanks
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, China, India, Japan, Brazil, GCC Countries, South Africa
Market Drivers	- Decentralization of diagnostics - Demand for patient-centric testing - Growth in genomic and population health initiatives
Customization Option	Available upon request